DOCSLIB.ORG

Iofendylate (BAN, Rinn) Media Are Usually Preferred

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Iofendylate (BAN, Rinn) Media Are Usually Preferred 1482 Contrast Media Sodium Iodamide (BANM, rINNM) Because it is slowly metabolised to release iodine, iodised oil is Iodixanol is usually available as a solution containing between Iodamida sódica; Iodamide Sodique; Iodamide Sodium; Natrii Io- used in the management of iodine deficiency (p.2170). 30.5 and 65.2% of iodixanol (equivalent to between 150 and 320 mg/mL of iodine). The dose and strength used vary accord- Infertility. For reference to the use of iodised oil in the manage- damidum. ing to the procedure and route. Натрий Йодамид ment of infertility, see Hysterosalpingography under Adverse Ef- fects and Precautions, above. ◊ References. C12H10I3N2NaO4 = 649.9. CAS — 10098-82-5. Malignant neoplasms. Intra-arterial injection of iodised oil 1. Spencer CM, Goa KL. Iodixanol: a review of its pharmacody- namic and pharmacokinetic properties and diagnostic use as an ATC — V08AA03. has been used in both the diagnosis and management of malig- x-ray contrast medium. Drugs 1996; 52: 899–927. ATC Vet — QV08AA03. nant neoplasms of the liver (p.667). After injection into the he- patic artery, iodised oil is selectively retained by hepatic carcino- Preparations Description. Sodium iodamide contains about 58.6% of I. mas and may have a role as an adjunct to computed tomography USP 31: Iodixanol Injection. Profile for both diagnosis and monitoring.1-3 It has also been used in the Proprietary Preparations (details are given in Part 3) Iodamide is an ionic monomeric iodinated radiographic contrast management of hepatic carcinoma,2,4 either to increase the reten- Austral.: Visipaque; Austria: Visipaque; Belg.: Visipaque; Braz.: Visi- medium (see p.1474). It is used in many procedures and may be tion of antineoplastics (chemoembolisation),5 or to provide tar- paque†; Canad.: Visipaque; Chile: Visipaque; Cz.: Visipaque; Denm.: Visi- given intravenously or by other routes, for example by instilla- 6 paque; Fin.: Visipaque; Fr.: Visipaque; Ger.: Visipaque; Gr.: Visipaque; geted delivery of radioactive iodine. Hung.: Visipaque; Israel: Visipaque; Ital.: Visipaque; Neth.: Visipaque; tion into the bladder or uterus; it has also been used for computed 1. Dalla Palma L. Diagnostic imaging and interventional therapy of Norw.: Visipaque; NZ: Visipaque; Port.: Visipaque; Rus.: Visipaque tomography. hepatocellular carcinoma. Br J Radiol 1998; 71: 808–18. (Визипак)†; Spain: Visipaque; Swed.: Visipaque; Switz.: Visipaque; UK: It is usually given as a 24 to 65% solution of the meglumine salt, 2. Ryder SD. Guidelines for the diagnosis and treatment of hepato- Visipaque; USA: Visipaque. or as a mixture of the sodium and meglumine salts; solutions of cellular carcinoma (HCC) in adults. Gut 2003; 52 (suppl): iii1–iii8. Also available at: http://www.bsg.org.uk/ the sodium salt have also been used. The dose varies according pdf_word_docs/hcc.pdf (accessed 27/03/06) to the procedure and route. 3. Zheng X-H, et al. Detection of hypervascular hepatocellular car- Iodoxamic Acid (BAN, USAN, rINN) Preparations cinoma: comparison of multi-detector CT with digital subtrac- tion angiography and Lipiodol CT. World J Gastroenterol 2005; Acide Iodoxamique; Ácido iodoxámico; Acidum Iodoxamicum; Proprietary Preparations (details are given in Part 3) 11: 200–203. B-10610; Jodoksaamihappo; Jodoxamsyra; SQ-21982. 3,3′- Austria: Uromiro; Ital.: Isteropac ER; Opacist ER; Uromiro 24%, 36%, and 4. Trinchet JC, et al. Review article: intra-arterial treatments in pa- (4,7,10,13-Tetraoxahexadecanedioyldiamino)bis(2,4,6-tri-iodo- 300†; Uromiro 300 Sodico†; Uromiro 340 and 420†; Switz.: Isteropac†; tients with hepatocellular carcinoma Aliment Pharmacol Ther benzoic acid). Opacist ER†; Uromiro†; Venez.: Angiomiron†; Uromiron. 2003; 17 (suppl 2): 111–118. 5. Group d’Etude et de Traitement du Carcinome Hépatocellulaire. Йодоксамовая Кислота A comparison of Lipiodol chemoembolization and conservative C26H26I6N2O10 = 1287.9. treatment for unresectable hepatocellular carcinoma. N Engl J CAS — 31127-82-9. Iodised Oil Med 1995; 332: 1256–61. ATC — V08AC01. Aceite yodado; Ethiodized Oil. 6. Lau WY, et al. Adjuvant intra-arterial iodine-131-labelled lipi- odol for resectable hepatocellular carcinoma: a prospective ran- ATC Vet — QV08AC01. CAS — 8001-40-9 (iodised oil); 8008-53-5 (ethiodized oil domised trial. Lancet 1999; 353: 797–801. injection). ATC — V08AD01. Preparations ATC Vet — QV08AD01. BP 2008: Iodised Oil Fluid Injection; USP 31: Ethiodized Oil Injection. Description. Iodised oil is an iodine addition product of the Proprietary Preparations (details are given in Part 3) ethyl esters of the fatty acids obtained from poppy-seed oil. It Arg.: Lipiodol; Austral.: Lipiodol; Austria: Lipiodol; Belg.: Lipiodol; Braz.: contains about 35 to 39% of combined iodine. Lipiodol†; Chile: Lipiodol; Cz.: Lipiodol; Denm.: Lipiodol; Fr.: Lipiodol; Incompatibility. Because of its solvent action on polystyrene, Ger.: Lipiodol; Gr.: Lipiodol; Hung.: Lipiodol; Israel: Lipiodol; Ital.: Lipi- odol; Neth.: Lipiodol; Norw.: Lipiodol†; NZ: Lipiodol; Port.: Lipiodol; iodised oil injection should not be given in syringes made with Switz.: Lipiodol; UK: Lipiodol; USA: Ethiodol; Venez.: Lipiodol. polystyrene. Adverse Effects and Precautions Description. Iodoxamic acid contains about 59.1% of I. The risk of hypersensitivity reactions or iodism is greater after Iodixanol (BAN, USAN, rINN) the use of iodised oil than after water-soluble iodinated contrast Meglumine Iodoxamate (BANM, rINNM) ′ media such as the amidotrizoates. Pulmonary oil embolism is re- 2-5410-3A; Iodixanolum; Jodiksanoli; Jodixanol. 5,5 -[(2-Hydrox- Dimeglumine Iodoxamate; Iodoxamate de Méglumine; Iodoxa- ytrimethylene)bis(acetylimino)]bis[N,N′-bis(2,3-dihydroxypro- ported to be relatively frequent after lymphography but is not mate Meglumine (USAN); Iodoxamato de meglumina; Meglumini usually severe; however, hypotension, tachycardia, and pulmo- pyl)-2,4,6-triiodoisophthalamide]. Iodoxamas. The di(N-methylglucamine) salt of iodoxamic acid. nary oedema and infarction may occur rarely and deaths have Йодиксанол been reported in patients with pulmonary disease. Chemical Меглумина Йодоксамат C35H44I6N6O15 = 1550.2. C H I N O ,(C H NO ) = 1678.3. pneumonitis, oedema, granuloma formation, and goitre have oc- CAS — 92339-11-2. 26 26 6 2 10 7 17 5 2 curred. CAS — 51764-33-1. ATC — V08AB09. ATC — V08AC01. Great care must be taken to avoid vascular structures, because of ATC Vet — QV08AB09. the danger of oil embolism; it should therefore not be used in ATC Vet — QV08AC01. areas affected by haemorrhage or local trauma. Iodised oil should Description. Meglumine iodoxamate contains about 45.4% of I. be used with care in patients with thyroid dysfunction or a history HO OH Profile of allergic reactions. Use may interfere with thyroid-function Iodoxamic acid is an ionic dimeric iodinated radiographic con- tests for several months. OH trast medium (p.1474) that has been used intravenously as the Hysterosalpingography. The use of oily contrast media such OH OHN OHN meglumine salt for cholecystography and cholangiography. as iodised oil for hysterosalpingography has been associated with serious adverse effects, including tubal occlusion,1 and cer- I I I IHO 2,3 ebral and pulmonary oil embolism, and water-soluble contrast H O N Iofendylate (BAN, rINN) media are usually preferred. However, diagnostic hysterosalp- N N OH ingography using iodised oil has been associated with an in- Ethyl Iodophenylundecylate; Iodophendylate; Iofendilato; Iofend- 4 5,6 NH I OH I O crease in fertility and randomised trials using iodised oil for HC O HC O ylatum; Iophendylate; Jofendylaatti; Jofendylat. A mixture of ster- treatment in patients with unexplained infertility have found a OH eoisomers of ethyl 10-(4-iodophenyl)undecanoate. similar effect. HO Йофендилат 1. Wright FW, Stallworthy J. Female sterility produced by investi- gation. BMJ 1973; 3: 632. Description. Iodixanol contains about 49.1% of I. C19H29IO2 = 416.3. 2. Dan U, et al. Cerebral embolization and coma after hysterosalp- CAS — 99-79-6; 1320-11-2. ingography with oil-soluble contrast medium. Fertil Steril 1990; Pharmacopoeias. In US. ATC — V08AD04. 53: 939–40. USP 31 (Iodixanol). A white to off-white, amorphous, odour- ATC Vet — QV08AD04. 3. Uzun O, et al. Pulmonary and cerebral oil embolism after hyste- less, hygroscopic powder. Freely soluble in water. Store at a tem- rosalpingography with oil soluble contrast medium. Respirology perature of 25°, excursions permitted between 15° and 30°. Pro- Description. Iofendylate contains about 30.5% of I. 2004; 9: 134–6. tect from light. Pharmacopoeias. In Chin. and US. 4. Johnson NP. A review of the use of lipiodol flushing for unex- . A colourless to pale yellow, viscous liq- plained infertility. Treat Endocrinol 2005; 4: 233–43. Adverse Effects, Treatment, and Precautions USP 31 (Iophendylate) 5. Nugent D, et al. A randomized controlled trial of tubal flushing See under the amidotrizoates, p.1475. For adverse effects relat- uid, darkening on long exposure to air. Is odourless or has a faint- with lipiodol for unexplained infertility. Fertil Steril 2002; 77: ing to the use of nonionic contrast media such as iodixanol for ly ethereal odour. Very slightly soluble in water; freely soluble in 173–5. myelography, see under Iohexol (p.1483). alcohol, in chloroform, in ether, and in benzene. Store in airtight 6. Johnson NP, et al. The FLUSH trial—flushing with lipiodol for containers at a temperature of 25°, excursions permitted between unexplained (and endometriosis-related) subfertility
Load more

Recommended publications
  • Reference List Concerning Spinal Adhesive Arachnoiditis
    SPINAL ADHESIVE ARACHNOIDITIS RMA ID Reference List for RMA363-2 as at June 2020 Number Abel TJ, Howard MA 3rd, Menezes A (2014). Syringomyelia and spinal arachnoiditis resulting from aneurysmal subarachnoid hemorrhage: 94310 Report of two cases and review of the literature. J Craniovertebr Junction Spine, 5(1): 47-51. Abhinav K, Bradley M, Aquilina K, et al (2012). Spinal arachnoiditis and 72882 cyst formation with subarachnoid haemorrhage. Br J Neurosurg, 26(4): 574-5. Abouleish E, Vega S, Blendinger I, et al (1975). Long-term follow-up of 94392 epidural blood patch. Anesth Analg, 54(4): 459-63. Agrawal A, Agrawal A, Agrawal C, et al (2006). An unusual spinal 59948 arachnoiditis. Clin Neurol Neurosurg, 108(8): 775-9. Al Maach N, Vogels OJ, Bollen TL, et al (2010). Arachnoiditis and 59949 communicating hydrocephalus as a complication of epidural blood patch. J Neurol, 257(4): 672-3. Aldrete JA (2003). Neurologic deficits and arachnoiditis following 59950 neuroaxial anesthesia. Acta Anaesthesiol Scand, 47(1): 3-12. Aldrete JA (2004). [Comment] Chronic adhesive arachnoiditis. Br J 59947 Anaesth, 93(2): 301; Author reply 301-3. Aldrete JA, Brown TL (1997). [Comment] Intrathecal hematoma and 94322 arachnoiditis after prophylactic blood patch through a catheter. Anesth Analg, 84(1): 233-4. Anderson TL, Morris JM, Wald JT, et al (2017). Imaging appearance of 94311 advanced chronic adhesive arachnoiditis: a retrospective review. AJR Am J Roentgenol, 209(3): 648-55. Anim-Somuah M, Smyth R, Howell C (2005). Epidural versus non- 60550 epidural or no analgesia in labour. Cochrane Database Syst Rev, 4: CD000331.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • I (Acts Whose Publication Is Obligatory) COMMISSION
    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Pharmacologyonline 2: 701-836 (2011) Newsletter Bradu and Rossini
    Pharmacologyonline 2: 701-836 (2011) Newsletter Bradu and Rossini CONTRAST AGENTS - FULL LIST OF THE 30 IODINATED PRODUCTS FOR WHICH REPORTS HAVE BEEN SENT OVER THE FIRST 40 YEARS OF THE WHO PHARMACOVIGILANCE SYSTEM, SUBDIVIDED INTO TWO 20-YEAR PERIODS. FOURTH WHO-ITA/ITA-OMS 2010-2011 CONTRIBUTION ON THE 30 BASIC AGGREGATED WHO SYSTEM-ORGAN CLASS DISORDERS (SOCDs), AND SUSPECTED+ ADVERSE REACTIONS AND EVENT PREFERRED NAMES (SADRs+) Dan Bradu and Luigi Rossini* Servizio Nazionale collaborativo WHO-ITA/ITA-OMS, Universita’ Politecnica delle Marche e Progetto di Farmacotossicovigilanza pre-, post-marketing, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary We have examined the PR-22 2010 data set, which includes 155,164 accepted SADRs associated with 30 iodinated contrast agents in use in the Countries participating in the WHO Pharmacovigilance Programme. The SADRs encompass 40 years, from 1968 to 2010, divided into two 20 year periods (1968-1989 and 1990-2010). The data, provided by the UMC, have been analysed in the framework of the Matlab software of correlation clustering leading to an objective classification based on the 30 standard WHO-SOCDs and preferred names. As reflected in the Title the first set of analyses regarded ATC-V08A sub-classes A (9 agents; 63,578 reports), B (12; 84,105), and C (8; 7,171). These were examined 701 Pharmacologyonline 2: 701-836 (2011) Newsletter Bradu and Rossini separately, then the results of the same procedure applied to the full matrix of 30 products and ―876 non empty‖ SADRs, including ATC-V08A sub-class D (1 agent; 310 reports) were displayed in the Appendices.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]